SEC Company Response from KAZIA THERAPEUTICS (KZIA) — Mar 26, 2026
KAZIA THERAPEUTICS LTD
Date: March 26, 2026 · CIK: 0001075880 · Accession: 0001213900-26-034709
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294392
Letter
Re:
March 26, 2026
Securities and Exchange Commission
F. Street, NE
Washington, D.C. 20549
Kazia Therapeutics Ltd. ("Company")
Registration Statement on Form F-3
File No. 333-294392
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Kazia Therapeutics Limited (the "Company") hereby requests that the effective date of the above-referenced registration statement (the "Registration Statement") be accelerated to March 27, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Lucosky Brookman LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Sebastian A. Bacon of Lucosky Brookman LLP at (732) 510-5382.
Sincerely,
KAZIA
THERAPEUTICS LIMITED
Show Raw Text
CORRESP
1
filename1.htm
March
26, 2026
Securities
and Exchange Commission
100
F. Street, NE
Washington,
D.C. 20549
Re:
Kazia
Therapeutics Ltd. ("Company")
Registration
Statement on Form F-3
File
No. 333-294392
VIA
EDGAR
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Kazia Therapeutics Limited (the "Company")
hereby requests that the effective date of the above-referenced registration statement (the "Registration Statement") be
accelerated to March 27, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Lucosky
Brookman LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration
request, the Company acknowledges that it is aware of its responsibilities under the Act.
If
you have any questions regarding this request, please contact Sebastian A. Bacon of Lucosky Brookman LLP at (732) 510-5382.
Sincerely,
KAZIA
THERAPEUTICS LIMITED
By:
/s/
John Friend
Name:
John
Friend
Title:
Chief
Executive Officer and Director
cc:
John
Friend, Chief Executive Officer and Director, Kazia Therapeutics Limited
Sebastian
A. Bacon, Esq., Lucosky Brookman LLP